Sponsor

Relay Therapeutics Inc.

United States 60 Hampshire Street, 02139-1548, United States

About the sponsor

Relay Therapeutics Inc. supports clinical research in advanced solid tumors with a focus on cancers driven by PIK3CA alterations, including disease settings where the mutation is identified in blood and/or tumor tissue.

PIK3CA-mutant cancer
Metastatic breast cancer
Hormone receptor positive, HER2-negative disease

The sponsor’s oncology portfolio centers on targeted treatment approaches for molecularly defined breast cancer and other solid malignancies.

About Specializations

Relay Therapeutics Inc. runs clinical trials in conditions such as Breast cancer, Breast cancer metastatic, Hormone receptor positive HER2 negative breast cancer, Lymphatic malformation, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

2 clinical trials

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo